N-(4-fluorobenzyl)-1-methylpiperidin-4-amine

Product Name:N-(4-fluorobenzyl)-1-methylpiperidin-4-amine

Synonyms: 4-fluorobenzyl)-(1-methylpiperidin-4-yl)amine;N-[(4-Fluorophenyl)methyl]-1-methyl-4-piperidinamine;4-(4-Fluorobenzylamino)-1-methylpiperidine;N-(4-fluorobenzyl)-1-Methylpiperidin-4-aMine;N-(4-flurobenzyl)-1-methylpiperidin-4-Amine; A6255;N-((4-fluorophenyl)methyl)-4-amino-1-methylpiperidine;4-(4-FLUOROBENZYLAMINO)-1-METHYLPIPERIDINE;(4-Fluoro-benzyl)-(1-methyl-piperidin-4-yl)-amine;

CAS:359878-47-0

MF:C13H19FN2

MW:222

EINECS:1592732-453-0

Mol File:359878-47-0.mol 

Boiling point: 305℃

Density:1.07

Fp:138℃

PSA:15.27000

LogP:2.33830

Density:1.07g/cm3

Boiling Point:304.8ºC at 760 mmHg

Flash Point:138.2ºC

Place of Origin:China

Type:Antidepressant

Grade Standard:Medicine Grade

Usage:Animal Pharmaceuticals

Model Number:API

Lead Time :Within 3 days after receive payment

Shipping item: CIP by courier to  your door(UPS, FedEx, DHL, EMS).

HS Code:29215900 

Package:100g,500g,1KG,10KG,100KG

Application:Pimavanserin intermediate:Pimavanserin , or pimavanserin tartate (USAN), marketed under the trade name Nuplazid, is a non-dopaminergic atypical antipsychotic developed by Acadia Pharmaceuticals for the treatment of Parkinson's disease psychosis and schizophrenia. Pimavanserin has a unique mechanism of action relative to other antipsychotics, behaving as a selective inverse agonist of the serotonin 5-HT2A receptor, with 40-fold selectivity for this site over the 5-HT2C receptor and no significant affinity or activity at the 5-HT2B receptor or dopamine receptors. The drug has met expectations for a Phase III clinical trial for the treatment of Parkinson's disease psychosis, and has completed Phase II trials for adjunctive treatment of schizophrenia alongside an antipsychotic medication.